down arrow

Abbott Laboratories

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0028241000
USD
125.40
0.11 (0.09%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

124.06125.57

52 Week

110.86141.23
Valuation
Technical
Day's Volume

CASH

5.23 M

Shareholding (Mar 2025)

FII

16.64%

Held by 612 FIIs

DII

50.53%

Held by 178 DIIs

Promoter

0.19%

How big is Abbott Laboratories?

22-Jun-2025

As of Jun 18, Abbott Laboratories has a market capitalization of $258.56 billion, with recent net sales of $42.34 billion and a net profit of $13.43 billion.

Market Cap: As of Jun 18, Abbott Laboratories has a market capitalization of 258,561.54 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Abbott Laboratories reported net sales of 42,344.00 million and a net profit of 13,432.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 47,664.00 million, while total assets were reported at 81,414.00 million.

Read More

What does Abbott Laboratories do?

22-Jun-2025

Abbott Laboratories is a large-cap company that develops and sells a wide range of healthcare products in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $10.36 billion and a net profit of $1.3 billion, with a market cap of approximately $258.56 billion.

Overview:<BR>Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products within the Pharmaceuticals & Biotechnology industry, categorized as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 10,358 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1,300 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 258,561.54 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.13 <BR>Return on Equity: 27.70% <BR>Price to Book: 5.30 <BR><BR>Contact Details:<BR>Address: 100 Abbott Park Rd, ABBOTT PARK IL: 60064-3500 <BR>Tel: 1 224 6676100 <BR>Website: https://www.abbott.com

Read More

Who are in the management team of Abbott Laboratories?

22-Jun-2025

As of March 2022, Abbott Laboratories' management team includes Executive Chairman Miles White, CEO Robert Ford, Lead Independent Director William Osborn, and Independent Directors Robert Alpern, Roxanne Austin, Sally Blount, and Michelle Kumbier. They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Abbott Laboratories includes the following individuals:<BR><BR>- Mr. Miles White, who serves as the Executive Chairman of the Board.<BR>- Mr. Robert Ford, who is the President, Chief Executive Officer, and Director.<BR>- Mr. William Osborn, who holds the position of Lead Independent Director.<BR>- Dr. Robert Alpern, who is an Independent Director.<BR>- Ms. Roxanne Austin, who is also an Independent Director.<BR>- Ms. Sally Blount, serving as an Independent Director.<BR>- Ms. Michelle Kumbier, who is another Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Abbott Laboratories technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Abbott Laboratories shows a mildly bullish technical trend, supported by a bullish monthly MACD and KST, while year-to-date it has outperformed the S&P 500 with a 16.15% return, though it has lagged in 3- and 5-year returns.

As of 10 October 2025, the technical trend for Abbott Laboratories has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish. The daily moving averages are bullish, suggesting short-term strength. The Bollinger Bands show a sideways trend on the weekly chart and mildly bullish on the monthly chart. The KST is bullish on both weekly and monthly time frames, but the OBV is mildly bearish weekly and shows no trend monthly. Overall, the technical stance is mildly bullish, driven primarily by the monthly MACD and KST indicators.<BR><BR>In terms of multi-period returns, Abbott has outperformed the S&P 500 year-to-date with a return of 16.15% compared to the S&P's 11.41%, but has lagged over longer periods such as the 3-year and 5-year returns.

Read More

Is Abbott Laboratories overvalued or undervalued?

25-Nov-2025

As of November 21, 2025, Abbott Laboratories is rated as attractive, fairly valued with a P/E ratio of 19, and has outperformed the S&P 500 year-to-date, despite a recent stock price decline and underperformance over the past three to five years.

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price.<BR><BR>In comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.62 times

 
2

Healthy long term growth as Operating profit has grown by an annual rate 13.45%

 
3

The company has declared Positive results for the last 3 consecutive quarters

4

With ROCE of 13.01%, it has a attractive valuation with a 4.85 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 258,487 Million (Large Cap)

stock-summary
P/E

19.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.12

stock-summary
Return on Equity

27.85%

stock-summary
Price to Book

5.11

Revenue and Profits:
Net Sales:
11,142 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,800 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.58%
0%
-5.58%
6 Months
-5.69%
0%
-5.69%
1 Year
8.13%
0%
8.13%
2 Years
19.21%
0%
19.21%
3 Years
16.01%
0%
16.01%
4 Years
-3.74%
0%
-3.74%
5 Years
16.22%
0%
16.22%

Abbott Laboratories for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Abbott Laboratories overvalued or undervalued?

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price. In comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods....

Read More

Is Abbott Laboratories overvalued or undervalued?

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price. In comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance....

Read More
Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics

Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics

Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.38, reflecting a year of notable highs and lows. Technical indicators present mixed signals, while Abbott's year-to-date performance has outpaced the S&P 500, though longer-term returns remain less competitive.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.51%
EBIT Growth (5y)
13.45%
EBIT to Interest (avg)
17.68
Debt to EBITDA (avg)
0.62
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.73
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
29.33%
Pledged Shares
0
Institutional Holding
81.24%
ROCE (avg)
151,913.83%
ROE (avg)
280,862.97%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
5.35
EV to EBIT
37.25
EV to EBITDA
25.84
EV to Capital Employed
4.85
EV to Sales
6.32
PEG Ratio
0.14
Dividend Yield
NA
ROCE (Latest)
13.01%
ROE (Latest)
27.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 244 Schemes (32.63%)

Foreign Institutions

Held by 612 Foreign Institutions (16.64%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 7.57% vs -5.61% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 38.46% vs -85.86% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11,142.00",
          "val2": "10,358.00",
          "chgp": "7.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,851.00",
          "val2": "2,444.00",
          "chgp": "16.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "135.00",
          "val2": "134.00",
          "chgp": "0.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-69.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,800.00",
          "val2": "1,300.00",
          "chgp": "38.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "186.10%",
          "val2": "163.00%",
          "chgp": "2.31%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.59% vs -8.12% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 134.19% vs -17.44% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "41,950.00",
          "val2": "40,109.00",
          "chgp": "4.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10,069.00",
          "val2": "9,678.00",
          "chgp": "4.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "603.00",
          "val2": "698.00",
          "chgp": "-13.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.00",
          "val2": "-188.00",
          "chgp": "101.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "13,351.00",
          "val2": "5,701.00",
          "chgp": "134.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "163.30%",
          "val2": "160.40%",
          "chgp": "0.29%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
11,142.00
10,358.00
7.57%
Operating Profit (PBDIT) excl Other Income
2,851.00
2,444.00
16.65%
Interest
135.00
134.00
0.75%
Exceptional Items
-69.00
0.00
Consolidate Net Profit
1,800.00
1,300.00
38.46%
Operating Profit Margin (Excl OI)
186.10%
163.00%
2.31%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 7.57% vs -5.61% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 38.46% vs -85.86% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
41,950.00
40,109.00
4.59%
Operating Profit (PBDIT) excl Other Income
10,069.00
9,678.00
4.04%
Interest
603.00
698.00
-13.61%
Exceptional Items
2.00
-188.00
101.06%
Consolidate Net Profit
13,351.00
5,701.00
134.19%
Operating Profit Margin (Excl OI)
163.30%
160.40%
0.29%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 4.59% vs -8.12% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 134.19% vs -17.44% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Abbott Laboratories stock-summary
stock-summary
Abbott Laboratories
Pharmaceuticals & Biotechnology
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products, including FreeStyle, PediaSure, Pedialyte, Similac, EleCare, ZonePerfect, Juven, Ensure and Glucerna. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. The cardiovascular's products include Portico, MitraClip, Dilatation Catheter, among others. The diagnostics products include IntelliFISH, Vysis ALK, STARLIMS, PathVysion, AlinIQ, among others.
Company Coordinates stock-summary
Company Details
100 Abbott Park Rd , ABBOTT PARK IL : 60064-3500
stock-summary
Tel: 1 224 6676100
stock-summary
https://www.abbott.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."